McKesson (MCK) Stock May Be 47% Undervalued On Cash Flow

McKesson has been a powerful compounder in recent years, and that kind of share price climb naturally raises a blunt question for investors about whether the current US$880.50 tag is properly grounded in the cash that the business can generate. With the focus squarely on its cash flows, the stock now invites a closer look at how much of that past success is already embedded in today’s valuation.

• Over the past 5 years, McKesson has delivered a total return of about 339.8%, which puts a lot of accumulated optimism on the line when you ask what its cash flows can realistically support.
• The company’s role in pharmaceutical distribution tends to turn a high volume of transactions into steady cash flow, which can support a valuation that leans heavily on how reliably those inflows keep arriving and how much capital it needs to keep them going.
• Prefer to judge McKesson on earnings? See what McKesson's 22.4x P/E says about the price.

For investors, the debate is whether McKesson’s current share price is fully supported by the cash flows implied by a Discounted Cash Flow (DCF) style intrinsic value estimate, or whether expectations built into that price have started to run ahead of those cash streams.

If you are questioning whether McKesson’s US$880.50 share price fully reflects its cash flows, a focused screen of other companies with similar quality filters can sharpen your comparison set through 30 high quality undervalued stocks.

Does McKesson Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) approach here focuses on the cash McKesson can return to shareholders over time rather than near term earnings swings. Over the last twelve months the business produced roughly $6.0b in free cash flow, and the 2 Stage Free Cash Flow to Equity model assumes that this pool of cash keeps growing from that base rather than shrinking.

Analyst projections in the DCF indicate free cash flow in the coming decade rising into the high single digit billions, with growth moderating in later years as McKesson matures. When those future cash streams are discounted back to today, the resulting intrinsic value estimate sits substantially above the current US$880.50 share price. This suggests the market is placing a relatively low multiple on the projected cash generation at the moment. Find out what McKesson could be worth using our Discounted Cash Flow (DCF) estimate.

The McKesson Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for McKesson pick up where the DCF puzzle leaves off and explain which assumptions on growth, margins and earnings would need to hold for the stock to end up worth materially more or less than today’s price, all housed on the Community page. Rather than anchoring on a single multiple or model output, each storyline lays out the specific drivers behind its fair value view so you can track those against actual results over time.

One of the top community narratives on McKesson: 10% undervalued

"Expansion of technology driven access platforms such as RxTS and CoverMyMeds, including programs for GLP 1 therapies and broader affordability and access solutions…"

Discover why this Narrative puts McKesson at 10% undervalued.

One more piece of the McKesson puzzle investors often miss

Valuation only tells part of the story for McKesson, since the research also flags specific risk checks that could change how you view the same cash flows and price tag. Take a closer look at 1 warning sign before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com